Month: July 2024

Uveitis Pipeline Insights and Analysis 2024: FDA Approvals and Clinical Trials Developments by DelveInsight | AbbVie, Novartis, Allergan, Bausch & Lomb, Santen Pharma, Eyegate Pharma

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Uveitis pipeline constitutes 15+ key companies continuously working towards developing 15+ Uveitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Uveitis Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Uveitis Market.

 

The Uveitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Uveitis Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Uveitis treatment therapies with a considerable amount of success over the years. 

  • Uveitis companies working in the treatment market are Priovant Therapeutics, Inc., ACELYRIN Inc., Bio-Thera Solutions, Eli Lilly and Company, Massachusetts Eye Research, Alumis Inc, Quan Dong Nguyen, Soligenix, Ganzhou Hemay Pharmaceutical, Amgen, and others, are developing therapies for the Uveitis treatment 

  • Emerging Uveitis therapies in the different phases of clinical trials are- Brepocitinib PO QD, Izokibep, QLETLI, Baricitinib, Ixekizumab Prefilled Syringe, ESK-001, OCS-01, Dusquetide, Hemay005, Apremilast, and others are expected to have a significant impact on the Uveitis market in the coming years.   

  • In April 2024, Roivant and Priovant Therapeutics announced positive results from the Phase II NEPTUNE clinical trial of brepocitinib for non-anterior non-infectious uveitis (NIU). The double-blind trial included 26 participants with active NIU, who were randomized in a 2:1 ratio to receive either 45mg or 15mg of brepocitinib daily. The study also included an initial prednisone burst of 60mg per day for two weeks, followed by a six-week tapering period.

  • In January 2024, Tarsier Pharma, Ltd., a clinical-stage ophthalmic biopharmaceutical company specializing in first-in-class therapies for blinding ocular diseases, announced that it has received agreement from the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA). This agreement pertains to the clinical trial protocol and planned statistical analysis for the Tarsier-04 Phase 3 trial, which will evaluate TRS01 eye drops for treating non-infectious uveitis, including uveitic glaucoma.

 

Uveitis Overview

Uveitis is an inflammation of the uvea, the middle layer of the eye that consists of the iris, ciliary body, and choroid. It can also involve adjacent structures like the retina, optic nerve, and vitreous humor.

 

Get a Free Sample PDF Report to know more about Uveitis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/uveitis-pipeline-insight

 

Emerging Uveitis Drugs Under Different Phases of Clinical Development Include:

  • Brepocitinib PO QD: Priovant Therapeutics, Inc.

  • Izokibep: ACELYRIN Inc.

  • QLETLI: Bio-Thera Solutions

  • Baricitinib: Eli Lilly and Company

  • Ixekizumab Prefilled Syringe: Massachusetts Eye Research

  • ESK-001: Alumis Inc

  • OCS-01: Quan Dong Nguyen

  • Dusquetide: Soligenix

  • Hemay005: Ganzhou Hemay Pharmaceutical

  • Apremilast: Amgen

 

Uveitis Route of Administration

Uveitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral

  • Parenteral

  • Intravenous

  • Subcutaneous

  • Topical

 

Uveitis Molecule Type

Uveitis Products have been categorized under various Molecule types, such as

  • Recombinant fusion proteins

  • Small molecule

  • Monoclonal antibody

  • Peptide

  • Polymer

  • Gene therapy

 

Uveitis Pipeline Therapeutics Assessment

  • Uveitis Assessment by Product Type

  • Uveitis By Stage and Product Type

  • Uveitis Assessment by Route of Administration

  • Uveitis By Stage and Route of Administration

  • Uveitis Assessment by Molecule Type

  • Uveitis by Stage and Molecule Type

 

DelveInsight’s Uveitis Report covers around 15+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

 

Further Uveitis product details are provided in the report. Download the Uveitis pipeline report to learn more about the emerging Uveitis therapies

 

Some of the key companies in the Uveitis Therapeutics Market include:

Key companies developing therapies for Uveitis are – AbbVie Inc., Novartis AG, Allergan Inc., Bausch & Lomb Incorporated, Santen Pharmaceutical Co. Ltd, Eyegate Pharmaceuticals Inc., Regeneron Pharmaceuticals, Eyepoint Pharmaceuticals Inc., Alimera Sciences Inc., and others.

 

Uveitis Pipeline Analysis:

The Uveitis pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Uveitis with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Uveitis Treatment.

  • Uveitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Uveitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Uveitis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Uveitis drugs and therapies

 

Uveitis Pipeline Market Strengths

  • The remarkable advances in ocular immunology over the past decades have led to a better understanding of the molecular mechanisms that underlie etiology and susceptibility to uveitis

  • New drugs with diverse mechanisms of action and routes of administration have been approved in the recent past, improving the treatment regime

 

Uveitis Pipeline Market Opportunities

  • Opportunity for companies to implement knowledge from recent advances in understanding the etiologies associated with uveitis to evaluate potential drugs with novel targets

  • Biomarker discovery and proteomics provide potential targets for therapeutic intervention by the drugs that are available and accessible, besides providing information about the drug that can be avoided

 

Scope of Uveitis Pipeline Drug Insight    

  • Coverage: Global

  • Key Uveitis Companies: Priovant Therapeutics, Inc., ACELYRIN Inc., Bio-Thera Solutions, Eli Lilly and Company, Massachusetts Eye Research, Alumis Inc, Quan Dong Nguyen, Soligenix, Ganzhou Hemay Pharmaceutical, Amgen, and others

  • Key Uveitis Therapies: Brepocitinib PO QD, Izokibep, QLETLI, Baricitinib, Ixekizumab Prefilled Syringe, ESK-001, OCS-01, Dusquetide, Hemay005, Apremilast, and others

  • Uveitis Therapeutic Assessment: Uveitis current marketed and Uveitis emerging therapies

  • Uveitis Market Dynamics: Uveitis market drivers and Uveitis market barriers 

 

Request for Sample PDF Report for Uveitis Pipeline Assessment and clinical trials

 

Table of Contents

1. Uveitis Report Introduction

2. Uveitis Executive Summary

3. Uveitis Overview

4. Uveitis- Analytical Perspective In-depth Commercial Assessment

5. Uveitis Pipeline Therapeutics

6. Uveitis Late Stage Products (Phase II/III)

7. Uveitis Mid Stage Products (Phase II)

8. Uveitis Early Stage Products (Phase I)

9. Uveitis Preclinical Stage Products

10. Uveitis Therapeutics Assessment

11. Uveitis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Uveitis Key Companies

14. Uveitis Key Products

15. Uveitis Unmet Needs

16 . Uveitis Market Drivers and Barriers

17. Uveitis Future Perspectives and Conclusion

18. Uveitis Analyst Views

19. Appendix

20. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Uveitis Pipeline Insights and Analysis 2024: FDA Approvals and Clinical Trials Developments by DelveInsight | AbbVie, Novartis, Allergan, Bausch & Lomb, Santen Pharma, Eyegate Pharma

Cloud Gaming Market to Gain 45.8% CAGR, because of Enhanced Gaming Experience

“Skyquest Technology”
Cloud Gaming Market Size, Share, Growth Analysis, By Type(File Streaming, Video Streaming), By Device(Smartphones, Tablets, Gaming Consoles, PCs & Laptops), By Gamer Type(Casual Gamers, Avid Gamers, Lifestyle Gamers), By Deployment(Public Cloud, Hybrid Cloud, Private Cloud), By Offering(Infrastructure, Compute, Memory, Storage), By Gaming System(PlayStation, Stream My Game, Steam in Home Streaming, Remote Play), By Region – Industry Forecast 2024-2031

Cloud Gaming Market size was valued at USD 696.6 million in 2019 and is poised to grow from USD 1020 million in 2023 to USD 20940 million by 2031, growing at a CAGR of 45.8% in the forecast period (2024-2031).

Systems in the global cloud gaming market are less expensive options for players and developers of video games. By not needing to buy a physical console or PC to run a game on, cloud gamers can save money. Instead, subscribing for a cloud gaming service can be an alternative for buyers at a cheaper monthly rate, providing them with a store of pre-installed games that can also be played on their choice device or new location. A further benefit of cloud gaming services is thatit’sa great way to avoid unnecessary costs that come with buying storage devices, downloading games before installing them and managing their large sizes repeatedly in a timely fashion.

Download a detailed overview:

https://www.skyquestt.com/sample-request/cloud-gaming-market

Exploring the Dynamic Frontier of Cloud Gaming at a Global Scale

The market for cloud gaming across the globe is highlighted by a significant competition and presence of key players across different industry verticals. NVIDIA, Google, Microsoft and Sony are among the leading players in the industry with huge market share thanks to their robust technological capabilities and infrastructure. Industry pioneers like NVIDIA, Google, Microsoft, and Sony own large portionsof market share due to their significant technological proficiencyand infrastructure. Toimprove these competitors like Tencent and Amazon go for advanced platforms as well as smart partnerships. Among other things major players in communication sector such as Verizon or AT&T are exploring ingress ways through cloud gaming using existent network coverage as well as clientele. This system is enduringly vigorous due topeople’s requirements keep changing, which compels improvement in service and technology.

Innovation Battlegrounds by Gaming Titans and Trailblazers in Cloud Industry

The global cloud gaming market is extremely competitive, with both established players and up-and-coming innovators dominating the scene. The current global behemoths which include NVIDIA, Google, Microsoft and Sony with each using their advanced infrastructure as well as technological expertise in acquiring significant market portions are at the forefront. New participants such as Tencent and Amazon are on the competition opening new inventive platforms while forming strategic alliances.

Request Free Customization of this report:

https://www.skyquestt.com/speak-with-analyst/cloud-gaming-market

Further industry expansion is encouraged by telecom giants such as Verizon and AT&T, who rely on their existing user bases and networks. Services and technology continue to be developed thanks to this universe of international partners, ensuring a vibrant and competitive market that caters for evolving global player demands.

Gaming Horizons Explored between Titans and Pioneers in Cloud Gaming

Utilising its state-of-the-art GPU technology, NVIDIA, a leader in the global cloud gaming market, offers high-performance cloud gaming experiences with GeForce NOW. Google’s Stadia platform provides a demonstration of the firm’s strengths by using its vast infrastructure and expertise in managing data to ensure smooth gaming across different devices. Xbox Cloud Gaming is driven by Microsoft’s Azure cloud platform. It underscores the fact that Azure is Microsoft’s major cloud gaming investment point in its infrastructure. Sony has dominance as seen with PlayStation Now where several games can be streamed using devices including these provided by PlayStation. Cloud gaming investments in platforms like Blacknut and Vortex demonstrate Tencent’s aggressive market entry.

View report summary and Table of Contents (TOC):

https://www.skyquestt.com/report/cloud-gaming-market

Cost-Efficient Innovations, Revolutionizing Gaming Accessibility

The gaming landscape has completely been revolutionized by innovative systems that are dynamic in the world of cloud gaming. The developers and players can access these affordable alternatives without expensive consoles or PCs. They can be played on several devices and from anywhere whereby cloud gaming services come with a wide range of games available at very low prices. It also slashes storage and bandwidth costs by dramatically reducing them, thus cutting down on planning for future storage and download times. The market for cloud gaming is always changing, providing a competitive landscape for both industry giants and new innovators where the needs of gamers from around the world are met on an ongoing basis.

Related Reports:

Cyber Security Market

Visit Our Website: https://www.skyquestt.com/

Media Contact
Company Name: Skyquest Technology
Contact Person: Mr. Jagraj Singh
Email: Send Email
Phone: +1 351-333-4748
Address:1 Apache Way, Westford,
Country: United States
Website: https://www.skyquestt.com/report/cloud-gaming-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cloud Gaming Market to Gain 45.8% CAGR, because of Enhanced Gaming Experience

Pharmaceutical Membrane Filtration Market worth $19.6 billion by 2029 | MarketsandMarkets™

“Asia Pacific is anticipated to register fastest growth in the pharmaceutical membrane filtration owing to the increasing technological advancement in nanofiber technologies, manufacturing facility expansions by pharmaceutical companies, high government investments & fundings for R&D, and growing biotechnology industries.”
Browse 652 market data Tables and 55 Figures spread through 502 Pages and in-depth TOC on “Pharmaceutical Membrane Filtration Market by Product (Filters (PES, PVDF, Nylon), Systems (Single use)), Technique (Microfiltration, Ultrafiltration), Application (API, Vaccines), Type (Sterile, Non Sterile), Scale of Operation – Global Forecast to 2029

Pharmaceutical Membrane Filtration Market in terms of revenue was estimated to be worth $10.6 billion in 2024 and is poised to reach $19.6 billion by 2029, growing at a CAGR of 13.1% from 2024 to 2029 according to a new report by MarketsandMarkets™. Some factors contributing to the growth of the global market includes increasing adoption of single use membrane filters coupled by high purity requirements among end users, increasing R&D spending by government and private organizations, and increasing regulations for membrane filter’s safety by regulatory bodies. Despite this, issues such as membrane fouling, and large capital investment are expected to hinder market growth.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=255408031

The polyethersulfone (PES) membrane filters segment accounted for the largest share of the membrane filters segment in the pharmaceutical membrane filtration market in 2023.

Based on products, the pharmaceutical membrane filtration market is segmented into membrane filters, systems, and other products. Membrane filters segment dominated the market in 2023 and is expected to dominate the market in the forecast period. Membrane filters are further segmented based on material into polyethersulfone (PES) membrane filters, polyvinylidene difluoride (PVDF) membrane filters, nylon membrane filters, polytetrafluoroethylene (PTFE) membrane filters, mixed cellulose ester & cellulose acetate (MCE & CA) membrane filters, polycarbonate track-etched (PCTE) membrane filters, and other membrane filters (PP, PC, CN, gelatin, PETE, and RC). Among these, PES membrane filters are most widely used due to their hydrophilic nature and high flow rates.

The microfiltration segment is estimated to register the highest growth rate during the forecast period in the pharmaceutical membrane filtration market.

Based on technique, the pharmaceutical membrane filtration market is segmented into microfiltration, ultrafiltration, nanofiltration, and other techniques. The other techniques segment includes reverse osmosis and ion exchange. The microfiltration segment is estimated to register the highest growth rate during the forecast period. In the pharmaceutical industry, microfiltration finds applications in clarification, purification of cell broths, the separation of cell debris, and the separation of macromolecules. The technique is used in harvesting cells in upstream bioprocessing.

The Asia Pacific region is the fastest-growing region of the pharmaceutical membrane filtration market in 2023.

Based on the region, the pharmaceutical membrane filtration market is segmented into major regions: North America, Europe, Asia Pacific, Latin America, Middle East and Africa. The Asia Pacific is anticipated to register fastest growth in the pharmaceutical membrane filtration owing to the increasing technological advancement in nanofiber technologies, manufacturing facility expansions by pharmaceutical companies, high government investments & fundings for R&D, and growing biotechnology industries.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=255408031

 

Key Market Players of Pharmaceutical Membrane Filtration Industry:

Key players in the pharmaceutical membrane filtration market include Merck KGaA (Germany), Danaher Corporation (US), Sartorius AG (Germany), Thermo Fisher Scientific, Inc. (US), 3M Company (US), Parker Hannifin Corporation (US), Repligen Corporation (US), Asahi Kasei Corporation (Japan), Eaton Corporation plc (Ireland), GEA Group (Germany), Corning Incorporated (US), Alfa Laval Corporate AB (Sweden), Donaldson Company, Inc. (US), Saint-Gobain (France), MANN+HUMMEL International GmbH & Co. KG (Germany), Meissner Filtration Products, Inc. (US), Cole-Parmer Instrument Company, LLC (US), Applexion (France), Cantel Medical Corp. (US), W. L. Gore & Associates Inc. (US), Membrane Solutions (US), Amazon Filters Ltd. (UK), Toyo Roshi Kaisha, Ltd. (Japan), Porvair plc (UK), Sterlitech Corporation (US), Synder Filtration, Inc. (US), Graver Technologies, LLC (US), Koch Membrane Systems, Inc. (US), Nupore Filtration Systems (India), and Cobetter Filtration Equipment Co., Ltd. (China).

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side- 70% and Demand Side 30%
  • By Designation: Managers – 45%, CXO & Directors – 30%, and Executives – 25%
  • By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10% and Middle East & Africa- 5%

Recent Developments of Pharmaceutical Membrane Filtration Industry:

  • Repligen Corporation (US) launched a holder-free, self-contained tangential flow filtration (TFF) device for the advancement of downstream flat sheet TFF technology for ultrafiltration and diafiltration (UF/DF).
  • Cytiva (US) announced the opening of a 33,000 ft2 manufacturing facility in Pune, India. The new facility will manufacture bioprocessing equipment such as tangential flow, virus filtration, and inactivation systems.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=255408031

Related Reports:

https://www.prnewswire.com/news-releases/pharmaceutical-membrane-filtration-market-worth-19-6-billion–marketsandmarkets-302085009.html

https://www.globenewswire.com/news-release/2024/03/29/2854723/0/en/Pharmaceutical-Membrane-Filtration-Market-is-Expected-to-Reach-19-6-billion-MarketsandMarkets.html

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/pharmaceutical-membrane-filtration-market-255408031.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pharmaceutical Membrane Filtration Market worth $19.6 billion by 2029 | MarketsandMarkets™

Cloud Services Market to Gain 16.8% CAGR, Considering Rising Mobile Device Penetration Globally

“Skyquest Technology”
Cloud Services Market Size, Share, Growth Analysis, By Service Model(Infrastructure as a Service (Primary Storage, Disaster Recovery and Backup, Archiving, Compute)), By Deployment Model(Private, Hybrid, Public, Others), By Enterprise Size(Large Enterprise Size, Small & Large Enterprise Size), By Vertical(BFSI, IT & Telecommunications, Government, Retail), By Region – Industry Forecast 2024-2031

Cloud Services Market size was valued at USD 484.23 billion in 2022 and is poised to grow from USD 565.58 billion in 2023 to USD 1959.01 billion by 2031, at a CAGR of 16.8% during the forecast period (2024-2031).

Organizations’ perception that their data is safer in-house data centers than on virtual cloud networks is the main barrier to the expansion of the global cloud services market. Data placement and management are two limiting variables that must be appropriately resolved to raise market income. One of the biggest target markets for cloud services is the developing world, which has steadily developed into a centre for IT services. This presents an opportunity for the market for cloud services. Furthermore, a significant expansion in the number of small and medium-sized businesses will ultimately cause these areas to adopt cloud services at a higher rate.

Download a detailed overview:

https://www.skyquestt.com/sample-request/cloud-services-market

Redefining Frontiers and their Vertical Mastery

In the ever-changing global market for cloud services, different companies are dominant in different industry sectors. AWS, Microsoft Azure and Google Cloud Platform are the leaders in the market for platforms that allow Infrastructure as a Service to be done. Meanwhile, Platform as a Service is provided by Salesforce, IBM and Oracle with specialised development and hosting platforms. These businesses like Microsoft, Salesforce or Adobe have specialized in delivering full software products under the development model of Software as a Service. Furthermore, up-and-coming firms like Tencent Cloud and Alibaba Cloud are becoming more popular and adding to the competitive scene with creative solutions catered to certain business requirements.

Navigating the Fast-evolving Cloud Service Landscape and its International Champions

A quick search on Google, and you will find that the global cloud services industry is highly competitive with many international players occupying various business niches. Some of the significant market players such as Amazon Web Services, Microsoft Azure and Google Cloud Platform dominate IaaS (Infrastructure as a Service) sector thanks to their reliable range of infrastructure solutions.

Request Free Customization of this report:

https://www.skyquestt.com/speak-with-analyst/cloud-services-market

Companies such as Salesforce, IBM, and Oracle provide specialized platforms for the development and deployment of applications under Platform as a Service (PaaS), which cater to a wide variety of customers worldwide. Global leaders in Software as a Service (SaaS), like Microsoft, Salesforce,and Adobe are noteworthy as their software solutions cover everything and are changing world business competition.

Unraveling the Global IaaS and PaaS Titans and Their Worldwide Impact

The Infrastructure as a Service (IaaS) market is still dominated by Amazon Web Services (AWS), which offers few numbers of services such as networking, storage, and processing power. AWS has customers globally and these include Netflix and Airbnb. With a robust worldwide footprint, Microsoft Azure offers scalable infrastructure solutions to major corporations like Coca-Cola and BMW. Google Cloud Platform is distinguished by its cutting-edge services, providing sophisticated analytics and machine learning tools to global clients like PayPal and Spotify. Salesforce’s Salesforce Platform provides customised application development and deployment solutions to businesses worldwide, such as T-Mobile and Unilever, in the Platform as a Service (PaaS) space.

View report summary and Table of Contents (TOC):

https://www.skyquestt.com/report/cloud-services-market

Embracing Opportunity and Overcoming Barriers in the Global Cloud Services Industry

Contrary to common misunderstandings about data safety, the global industry for cloud services is poised for enormous growth. If businesses want to fully utilise cloud services, they need to get past three obstacles. Cloud service firms stand a big chance with the fast-growing IT sector in emerging countries. It is anticipated that the rates of adoption or take-up among small and medium enterprises will be high as cloud services are enjoying greater market penetration. Through its innovative solutions and tailor-made propositions; this worldwide cloud setup transforms industries as well as corporate mindsets.

Related Reports:

Augmented, Virtual and Mixed Reality Market

Visit Our Website: https://www.skyquestt.com/

Media Contact
Company Name: Skyquest Technology
Contact Person: Mr. Jagraj Singh
Email: Send Email
Phone: +1 351-333-4748
Address:1 Apache Way, Westford,
Country: United States
Website: https://www.skyquestt.com/report/cloud-services-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cloud Services Market to Gain 16.8% CAGR, Considering Rising Mobile Device Penetration Globally

Commercial Aviation Market to Gain 4.43% CAGR Amidst Increasing Regulatory Pressures

“Skyquest Technology”
Commercial Aviation Market Size, Share, Growth Analysis, By Aircraft Type(Narrow-body aircraft, wide-body aircraft, regional aircraft, others), By Engine Type(Turbofan engines, turboprop engines), By Application(Passenger aircraft, cargo aircraft), By Region – Industry Forecast 2024-2031

Commercial Aviation Market size was valued at USD 182.22 Billion in 2022 and is poised to grow from USD 190.29 Billion in 2023 to USD 269.17 Billion by 2031, growing at a CAGR of 4.43% in the forecast period (2024-2031)

The strong growth trajectory of the global commercial aviation market has been occasioned by increased demand for air travel worldwide, technological advancements, and focus on sustainability. This industry is strategically positioned in addition to becoming more relevant in fostering cultural exchange, promoting economic development and ensuring world connectivity amidst dynamically changing market trends. Despite some worries about the environment, these projects aim to make air travel eco-friendlier and more long-lasting. It is projected that commercial air transport will experience enormous growth through infrastructure development and adopting new technologies, thereby propping up the global economy.

Download a detailed overview:

https://www.skyquestt.com/sample-request/commercial-aviation-market

Intense Rivalry in the World of Commercial Aviation

The global commercial aviation market is fiercely contested by key players such as Boeing, Airbus, and Embraer. These giants have established themselves as world leaders in this industry through vast product portfolios. Additionally, emerging businesses of Irkut and COMAC are attracting more customers while aircraft manufacturing, avionics manufacture, component suppliers or MRO are examples of business verticals. Three key competing aspects are avionics, lightweight materials, and fuel efficiency innovations. Variations in fuel prices, shifts in regulations, and shifting consumer preferences towards sustainability all impact market dynamics. Getting a competitive edge depends heavily on technology breakthroughs, mergers, and strategic alliances.

Innovation and Strategic Moves Define the Competitive Industry in Commercial Aviation

Well-known companies in the international aircraft market such as Boeing, Airbus and Embraer are engaged in fierce rivalry on account of their comprehensive product ranges and worldwide presence. That dominance is now being contested by new players such as COMAC as well as Irkut. Other major channels include avionics manufacturing, aircraft assembly works as well as supply of components and MRO community (maintenance repair organization) services.

Request Free Customization of this report:

https://www.skyquestt.com/speak-with-analyst/commercial-aviation-market

Gaining a competitive edge requires innovations in avionics, lightweight materials, and fuel efficiency. Variations in fuel charges, shifts in regulations, as well as the rise in demand for sustainable programs, are influencing the market dynamics. With technical developments, mergers and strategic partnerships being vital in such a highly competitive environment.

Strategic Innovation of Boeing, Airbus and Emerging Rivals in the Aviation Market

With their popular fuel-efficient and cutting-edge technology, Boeing’s 737 MAX and Airbus’s A320neo serve as prime examples of why they dominate the market. The regional plane Embraer’s E-Jet series contends in the regional jet sector whereas in the narrow-body market Boeing and Airbus have a lot of control. MRO services are quite necessary for instance companies like Lufthansa Technik are on top of airplane maintenance. There are instances when innovations such as those presented using composite material in Airbus’ A350 can prove its sustainability while Boeing’s ecoDemonstrator program also falls within such category. Collaborating with Embraer is one example of a strategic relationship that highlights attempts to improve technological capabilities and market positioning.

View report summary and Table of Contents (TOC):

https://www.skyquestt.com/report/commercial-aviation-market

Shaping the Future of Global Commercial Aviation Industry

The rise in world-wide demand for air transport services, technological advancement and an increasing preference for environmental conservation are some of the forces that are fuelling the significant growth trajectory of the global commercial aviation industry. A well innovated and adaptable industry to changing market situation will significantly contribute to enhance cross-border exchange culture development, pace of economic development and global cohesion Commercial aviation will continue to play a major role in the global economy and has a bright future with additional investments in technology and infrastructure. By addressing environmental issues, these programmes seek to maintain the long-term viability of air travel.

Related Reports:

Artificial Intelligence Market

Visit Our Website: https://www.skyquestt.com/

Media Contact
Company Name: Skyquest Technology
Contact Person: Mr. Jagraj Singh
Email: Send Email
Phone: +1 351-333-4748
Address:1 Apache Way, Westford,
Country: United States
Website: https://www.skyquestt.com/report/commercial-aviation-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Commercial Aviation Market to Gain 4.43% CAGR Amidst Increasing Regulatory Pressures

Offshore Support Vessel Market worth $36.3 Billion by 2029

The global offshore support vessel market is expected to grow from an estimated USD 25.6 billion in 2024 to USD 36.3 billion by 2029, at a CAGR of 7.2% during the forecast period.

The global Offshore Support Vessel Marketin terms of revenue was estimated to be worth $25.6 billion in 2024 and is poised to reach $36.3 billion by 2029, growing at a CAGR of 7.2% from 2024 to 2029 according to a new report by MarketsandMarkets™.

The global Offshore Support Vessel Market is anticipated to grow at a higher level. There are various drivers responsible for the growth of the market such as government policies and incentives and technological advancements among others. The rising global demand for energy, particularly from developing countries, pushes the need for increased offshore exploration and production, subsequently driving the OSV market.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1212

Shallow water application is expected to be the largest segment during the forecast period.

Maintenance and refurbishment of aging offshore infrastructure in shallow waters are critical activities that heavily rely on the support of offshore support vessels (OSVs). Over time, offshore installations such as oil platforms, pipelines, and production facilities deteriorate due to harsh marine conditions, necessitating regular upkeep to ensure their safety, efficiency, and compliance with environmental regulations. OSVs play a crucial role in these operations by providing the necessary transportation, logistical support, and specialized equipment needed for maintenance tasks.

These vessels are equipped to handle a wide range of activities, including inspection, repair, and replacement of structural components, as well as the deployment of divers and remotely operated vehicles (ROVs) for underwater work. Additionally, OSVs offer essential services such as supply runs, waste removal, and crew transport, ensuring that maintenance operations proceed smoothly and without interruption. The presence of reliable OSVs ensures that aging infrastructure can be effectively managed, reducing the risk of accidents and prolonging the operational lifespan of offshore assets. This ongoing demand for maintenance and refurbishment services drives the growth and development of the OSV market, particularly in regions with extensive shallow water installations.

Offshore Oil & Gas industry is expected to be the largest segment during the forecast period.

The expansion of exploration and production activities in emerging offshore markets, particularly in deepwater reserves and Arctic regions, is creating significant new opportunities for offshore support vessel operators and manufacturers. These frontier areas are attracting substantial investments from oil and gas companies seeking to tap into previously unexplored or underexplored hydrocarbon reserves.

Deepwater reserves, often found off the coasts of countries like Brazil, Guyana, and West Africa, present unique challenges and opportunities. The complex and demanding nature of deepwater drilling operations necessitates specialized support vessels equipped with advanced technology and capabilities. These vessels must be able to operate in harsh conditions, provide reliable support for drilling rigs, transport personnel and supplies, and ensure safety and efficiency in deepwater environments.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=1212

North America is expected to be the fastest growing region in the Offshore Support Vessel Market.

The relentless global demand for energy continues to drive significant growth in offshore exploration and production activities, especially in resource-rich regions like the Gulf of Mexico. This area’s abundant oil and gas reserves attract major energy companies and independent operators, making it a prime target for exploration and production initiatives. Offshore support vessels (OSVs) play a crucial role in these ventures, providing essential services such as transporting supplies, equipment, and personnel, as well as performing specialized functions like anchor handling and subsea construction support. Technological advancements in OSV design, including dynamic positioning systems and automated tools, have enhanced operational efficiency and safety, further boosting their importance in offshore operations.

Key Market Players of Offshore Support Vessel Industry:

Some of the major players in the Offshore Support Vessel Market are A.P. Moller-Maersk (Denmark), Tidewater Inc. (US), BOURBON (France), Edison Chouset Offshore (US), and Deltamarin Ltd (Europe). The major strategies adopted by these players include new product launches, acquisitions, contracts, agreements, partnerships, joint ventures, collaborations, investments, and expansions.

Get access to the latest updates on Offshore Support Vessel Companies and Offshore Support Vessel Industry Growth

About MarketsandMarkets™:

MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

Contact:

Mr. Rohan Salgarkar

MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA: +1-888-600-6441

Email: newsletter@marketsandmarkets.com

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/offshore-support-vessel-market-1212.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Offshore Support Vessel Market worth $36.3 Billion by 2029

Dyadic Intl (NASDAQ: DYAI) and Proliant Health Biologicals to Launch $6 Billion Serum Albumin Market Product in 2025

Dyadic International (NASDAQ: DYAI), a global leader in cell culture solutions, announced a strategic partnership with Proliant Health and Biologicals (PHB), a leading supplier of purified proteins for the nutrition, diagnostics, and cell culture sectors. Under the agreement, Proliant will provide Dyadic with $1.5 million upfront to develop high-volume, cost-effective cell culture products. The product is set to debut in the first half of 2025 in the $6 billion serum albumin market. 

These animal-free recombinant albumin products will be developed using Dyadic International’s advanced filamentous fungal microbial platforms. Dyadic will also receive a profit share from PHB’s sales of these products. Part of the initial milestone payment will fund commercialization efforts and technology transfer. The partnership will initially focus on launching recombinant human serum albumin products. 

Proliant Health and Biologicals, the world’s leading manufacturer of animal-derived proteins, specializes in producing animal extracts and multiple grades of “Fraction V” bovine serum albumin (BSA). Renowned for its unmatched consistency, traceability, and quality, Proliant is the preferred BSA supplier for industries such as in-vitro diagnostics, vaccine production, biopharmaceutical and medical device manufacturing, nutraceuticals, and life science research. 

In the June 28, 2024, news release, Dyadic International management expressed enthusiasm about the partnership with Proliant Health and Biologicals (PHB) for producing bovine serum albumin and other cell culture products. This collaboration highlights Dyadic’s strategic move to commercialize products and generate revenue in the alternative protein market in the near future.

Dyadic International’s protein product technology, combined with Proliant Health and Biologicals’ (PHB) strong market position, presents a significant opportunity to co-produce high-quality, cost-effective products at scale. PHB’s management noted a surge in demand for alternative protein sources in the life sciences and diagnostics industries in recent years. This partnership enables PHB to expand its product portfolio to include animal-free proteins and gain access to technology with unlimited innovation potential. 

These companies are active in the biotechnology and life sciences sector. Ocular Therapeutix, Inc. (NASDAQ: OCUL) develops treatments for eye diseases and conditions using its proprietary hydrogel technology. Abeona Therapeutics Inc. (NASDAQ: ABEO) focuses on creating gene and cell therapies for life-threatening rare genetic diseases. Geron Corporation (NASDAQ: GERN) is dedicated to developing cancer therapies, specifically targeting telomerase inhibitors. Inovio Pharmaceuticals, Inc. (NASDAQ: INO) specializes in the development of DNA-based immunotherapies and vaccines.

 

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content.”TSR” is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. “TSR” authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. “TSR” has not been compensated to produce content related to “Any Companies” appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Dyadic Intl (NASDAQ: DYAI) and Proliant Health Biologicals to Launch $6 Billion Serum Albumin Market Product in 2025

Mesothelioma Pipeline Dynamics 2024: FDA Approvals, Therapeutic Advances, by DelveInsight | GSK, Merck, Bristol-Myers Squibb, AstraZeneca, Roche, Novartis, Pfizer Inc., Eli Lilly and Company, J&J

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Mesothelioma pipeline constitutes 45+ key companies continuously working towards developing 50+ Mesothelioma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Mesothelioma Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Mesothelioma Market.

 

The Mesothelioma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Mesothelioma Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Mesothelioma treatment therapies with a considerable amount of success over the years. 

  • Mesothelioma companies working in the treatment market are The Netherlands Cancer Institute, Bristol-Myers Squibb, PrECOG, LLC., Memorial Sloan Kettering Cancer Center, ETOP IBCSG Partners Foundation, MedImmune LLC, Åslaug Helland, AstraZeneca, Oncotelic Inc., Hyogo Medical University, Trizell Ltd, RS Oncology LLC, Vivace Therapeutics, Inc, TCR2 Therapeutics, Sanofi, ImmVira Pharma Co. Ltd, TCR2 Therapeutics, CRISPR Therapeutics, Biotheus Inc., and others, are developing therapies for the Mesothelioma treatment 

  • Emerging Mesothelioma therapies in the different phases of clinical trials are- Pembrolizumab, Nivolumab, Durvalumab, Sacituzumab govitecan-hziy, Carboplatin, Tremelimumab, ipilimumab, Volrustomig, OT-101, Lenvatinib, rAd-IFN, RSO-021, VT3989, gavo-cel, THOR-707, T3011, TC-510, CTX131, PM8002, and others are expected to have a significant impact on the Mesothelioma market in the coming years.   

  • In March 2024, Ultimovacs, a clinical-stage biotechnology company, has released data from the Phase II NIPU trial of its UV1 cancer vaccine. This investigator-initiated, open-label, multi-center Phase II trial evaluated the impact of incorporating the UV1 cancer vaccine into second-line treatment with ipilimumab and nivolumab for patients with pleural mesothelioma.

  • In December 2023, Sellas Life Sciences, a US-based late-stage clinical biopharmaceutical company, announced that its Phase I study (NCT02737787) of galinpepimut-S combined with Opdivo (nivolumab) has successfully met its primary endpoint, showing improved overall survival in mesothelioma patients.

 

Mesothelioma Overview

Mesothelioma is a type of cancer that develops from the thin layer of tissue that covers many of the internal organs (mesothelium). The most common form is pleural mesothelioma, which affects the lining of the lungs and is often associated with exposure to asbestos fibers. Other less common forms include peritoneal mesothelioma (affecting the lining of the abdomen), pericardial mesothelioma (affecting the lining around the heart), and mesothelioma of the tunica vaginalis (affecting the lining of the testes).

 

Get a Free Sample PDF Report to know more about Mesothelioma Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/mesothelioma-pipeline-insight

 

Emerging Mesothelioma Drugs Under Different Phases of Clinical Development Include:

  • Pembrolizumab: The Netherlands Cancer Institute

  • Nivolumab: Bristol-Myers Squibb

  • Durvalumab: PrECOG, LLC.

  • Sacituzumab govitecan-hziy: Memorial Sloan Kettering Cancer Center

  • Carboplatin: ETOP IBCSG Partners Foundation

  • Tremelimumab: MedImmune LLC

  • ipilimumab: Åslaug Helland

  • Volrustomig: AstraZeneca

  • OT-101: Oncotelic Inc.

  • Lenvatinib: Hyogo Medical University

  • rAd-IFN: Trizell Ltd

  • RSO-021: RS Oncology LLC

  • VT3989: Vivace Therapeutics, Inc

  • gavo-cel: TCR2 Therapeutics

  • THOR-707: Sanofi

  • T3011: ImmVira Pharma Co. Ltd

  • TC-510: TCR2 Therapeutics

  • CTX131: CRISPR Therapeutics

  • PM8002: Biotheus Inc.

 

Mesothelioma Route of Administration

Mesothelioma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral

  • Parenteral

  • Intravenous

  • Subcutaneous

  • Topical

 

Mesothelioma Molecule Type

Mesothelioma Products have been categorized under various Molecule types, such as

  • Recombinant fusion proteins

  • Small molecule

  • Monoclonal antibody

  • Peptide

  • Polymer

  • Gene therapy

 

Mesothelioma Pipeline Therapeutics Assessment

  • Mesothelioma Assessment by Product Type

  • Mesothelioma By Stage and Product Type

  • Mesothelioma Assessment by Route of Administration

  • Mesothelioma By Stage and Route of Administration

  • Mesothelioma Assessment by Molecule Type

  • Mesothelioma by Stage and Molecule Type

 

DelveInsight’s Mesothelioma Report covers around 50+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

 

Further Mesothelioma product details are provided in the report. Download the Mesothelioma pipeline report to learn more about the emerging Mesothelioma therapies

 

Some of the key companies in the Mesothelioma Therapeutics Market include:

Key companies developing therapies for Mesothelioma are – Merck & Co., Inc., Bristol-Myers Squibb, AstraZeneca, Roche, Novartis, Pfizer Inc., Eli Lilly and Company, Johnson & Johnson, GlaxoSmithKline plc (GSK), AbbVie Inc., Sanofi, and others.

 

Mesothelioma Pipeline Analysis:

  • The Mesothelioma pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Mesothelioma with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Mesothelioma Treatment.

  • Mesothelioma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Mesothelioma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Mesothelioma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Mesothelioma drugs and therapies

 

Mesothelioma Pipeline Market Drivers

  • Advancements in Treatment, Targeted Therapies, Immunotherapy Innovations, Early Diagnosis Initiatives, Increased Awareness, are some of the important factors that are fueling the Mesothelioma Market.

 

Mesothelioma Pipeline Market Barriers

  • However, Limited Treatment Option, Diagnostic Challenges, High Development Costs, Patient Heterogeneity, Lack of Funding, and other factors are creating obstacles in the Mesothelioma Market growth.

 

Scope of Mesothelioma Pipeline Drug Insight    

  • Coverage: Global

  • Key Mesothelioma Companies: The Netherlands Cancer Institute, Bristol-Myers Squibb, PrECOG, LLC., Memorial Sloan Kettering Cancer Center, ETOP IBCSG Partners Foundation, MedImmune LLC, Åslaug Helland, AstraZeneca, Oncotelic Inc., Hyogo Medical University, Trizell Ltd, RS Oncology LLC, Vivace Therapeutics, Inc, TCR2 Therapeutics, Sanofi, ImmVira Pharma Co. Ltd, TCR2 Therapeutics, CRISPR Therapeutics, Biotheus Inc., and others

  • Key Mesothelioma Therapies: Pembrolizumab, Nivolumab, Durvalumab, Sacituzumab govitecan-hziy, Carboplatin, Tremelimumab, ipilimumab, Volrustomig, OT-101, Lenvatinib, rAd-IFN, RSO-021, VT3989, gavo-cel, THOR-707, T3011, TC-510, CTX131, PM8002, and others

  • Mesothelioma Therapeutic Assessment: Mesothelioma current marketed and Mesothelioma emerging therapies

  • Mesothelioma Market Dynamics: Mesothelioma market drivers and Mesothelioma market barriers 

 

Request for Sample PDF Report for Mesothelioma Pipeline Assessment and clinical trials

 

Table of Contents

1. Mesothelioma Report Introduction

2. Mesothelioma Executive Summary

3. Mesothelioma Overview

4. Mesothelioma- Analytical Perspective In-depth Commercial Assessment

5. Mesothelioma Pipeline Therapeutics

6. Mesothelioma Late Stage Products (Phase II/III)

7. Mesothelioma Mid Stage Products (Phase II)

8. Mesothelioma Early Stage Products (Phase I)

9. Mesothelioma Preclinical Stage Products

10. Mesothelioma Therapeutics Assessment

11. Mesothelioma Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Mesothelioma Key Companies

14. Mesothelioma Key Products

15. Mesothelioma Unmet Needs

16 . Mesothelioma Market Drivers and Barriers

17. Mesothelioma Future Perspectives and Conclusion

18. Mesothelioma Analyst Views

19. Appendix

20. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Mesothelioma Pipeline Dynamics 2024: FDA Approvals, Therapeutic Advances, by DelveInsight | GSK, Merck, Bristol-Myers Squibb, AstraZeneca, Roche, Novartis, Pfizer Inc., Eli Lilly and Company, J&J

Kidney Transplant Rejection Pipeline Forecast 2024: FDA Approvals, Therapies, and Leading Companies by DelveInsight | Veloxis Pharma, Eledon Pharma, Sangamo, Horizon Therapeutics, CSL Behring, Medeor

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Kidney Transplant Rejection pipeline constitutes 6+ key companies continuously working towards developing 8+ Kidney Transplant Rejection treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Kidney Transplant Rejection Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Kidney Transplant Rejection Market.

 

The Kidney Transplant Rejection Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Kidney Transplant Rejection Pipeline Report: 

  • Companies across the globe are diligently working toward developing novel Kidney Transplant Rejection treatment therapies with a considerable amount of success over the years. 

  • Kidney Transplant Rejection companies working in the treatment market are Veloxis Pharmaceuticals, Inc., Eledon Pharmaceuticals, Sangamo TherapeuticsInc., Horizon Therapeutics Plc, CSL Behring, Medeor Therapeutics, Inc, and others, are developing therapies for the Kidney Transplant Rejection treatment 

  • Emerging Kidney Transplant Rejection therapies in the different phases of clinical trials are- VEL-101, Tegoprubart, TX200, Dazodalibep, Clazakizumab, MDR-101, and others are expected to have a significant impact on the Kidney Transplant Rejection market in the coming years.   

  • In May 2024, Human Immunology Biosciences (HI-Bio) has announced positive results from its Phase II clinical trial of felzartamab for treating late antibody-mediated rejection (AMR) in kidney transplant recipients. This investigator-sponsored, double-blind, placebo-controlled study assessed the safety and tolerability of felzartamab in adults who developed late AMR at least six months after undergoing a kidney transplant.

  • In July 2023, Verici Dx, a clinical diagnostics developer for organ transplants, has achieved successful validation results from its prospective, blinded clinical validation study for Clarava. Clarava is a pre-transplant prognostic test that evaluates a patient’s immune response and assesses the risk of early kidney transplant rejection. The test leverages RNA sequencing and utilizes artificial intelligence to determine an RNA signature from gene expression.

 

Kidney Transplant Rejection Overview

Kidney transplant rejection is an allogeneic immune reaction that degrades the graft’s function and causes graft destruction. Patients who do not take their medicine as directed or who have insufficient immunosuppression frequently experience it. Chronic active antibody-mediated rejection (ABMR) and chronic active T cell-mediated rejection (TCMR) are the two main subtypes of kidney transplant rejection.

 

Get a Free Sample PDF Report to know more about Kidney Transplant Rejection Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/kidney-transplant-rejection-pipeline-insight

 

Emerging Kidney Transplant Rejection Drugs Under Different Phases of Clinical Development Include:

  • VEL-101: Veloxis Pharmaceuticals, Inc.

  • Tegoprubart: Eledon Pharmaceuticals, Inc.

  • TX200: Sangamo Therapeutics

  • Dazodalibep: Horizon Therapeutics Plc

  • Clazakizumab: CSL Behring

  • MDR-101: Medeor Therapeutics, Inc

 

Kidney Transplant Rejection Route of Administration

Kidney Transplant Rejection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral

  • Parenteral

  • Intravenous

  • Subcutaneous

  • Topical

  • Molecule Type

 

Kidney Transplant Rejection Molecule Type

Kidney Transplant Rejection Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

  • Product Type

 

Kidney Transplant Rejection Pipeline Therapeutics Assessment

  • Kidney Transplant Rejection Assessment by Product Type

  • Kidney Transplant Rejection By Stage and Product Type

  • Kidney Transplant Rejection Assessment by Route of Administration

  • Kidney Transplant Rejection By Stage and Route of Administration

  • Kidney Transplant Rejection Assessment by Molecule Type

  • Kidney Transplant Rejection by Stage and Molecule Type

 

DelveInsight’s Kidney Transplant Rejection Report covers around 8+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

 

Further Kidney Transplant Rejection product details are provided in the report. Download the Kidney Transplant Rejection pipeline report to learn more about the emerging Kidney Transplant Rejection therapies

 

Some of the key companies in the Kidney Transplant Rejection Therapeutics Market include:

Key companies developing therapies for Kidney Transplant Rejection are – Astellas Pharma Inc, Medeor Therapeutics Inc, Bristol-Myers Squibb Co, Junten Bio Co Ltd, OSE Immunotherapeutics, Sangamo Therapeutics Inc, Talaris Therapeutics Inc, Eledon Pharmaceuticals Inc, Hillhurst Biopharmaceuticals Inc, Alphamab Oncology, and others.

 

Kidney Transplant Rejection Pipeline Analysis:

The Kidney Transplant Rejection pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Kidney Transplant Rejection with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Kidney Transplant Rejection Treatment.

  • Kidney Transplant Rejection key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Kidney Transplant Rejection Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Kidney Transplant Rejection market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Kidney Transplant Rejection drugs and therapies

 

Kidney Transplant Rejection Pipeline Market Drivers

  • Rising Prevalence of chronic kidney diseases, increasing Number of Kidney Transplantations are some of the important factors that are fueling the Kidney Transplant Rejection Market.

 

Kidney Transplant Rejection Pipeline Market Barriers

  • However, lack of donor and knowledge, long waiting time for transplantation and other factors are creating obstacles in the Kidney Transplant Rejection Market growth.

 

Scope of Kidney Transplant Rejection Pipeline Drug Insight    

  • Coverage: Global

  • Key Kidney Transplant Rejection Companies: Veloxis Pharmaceuticals, Inc., Eledon Pharmaceuticals, Sangamo TherapeuticsInc., Horizon Therapeutics Plc, CSL Behring, Medeor Therapeutics, Inc, and others

  • Key Kidney Transplant Rejection Therapies: VEL-101, Tegoprubart, TX200, Dazodalibep, Clazakizumab, MDR-101, and others

  • Kidney Transplant Rejection Therapeutic Assessment: Kidney Transplant Rejection current marketed and Kidney Transplant Rejection emerging therapies

  • Kidney Transplant Rejection Market Dynamics: Kidney Transplant Rejection market drivers and Kidney Transplant Rejection market barriers 

 

Request for Sample PDF Report for Kidney Transplant Rejection Pipeline Assessment and clinical trials

 

Table of Contents 

1. Kidney Transplant Rejection Report Introduction

2. Kidney Transplant Rejection Executive Summary

3. Kidney Transplant Rejection Overview

4. Kidney Transplant Rejection- Analytical Perspective In-depth Commercial Assessment

5. Kidney Transplant Rejection Pipeline Therapeutics

6. Kidney Transplant Rejection Late Stage Products (Phase II/III)

7. Kidney Transplant Rejection Mid Stage Products (Phase II)

8. Kidney Transplant Rejection Early Stage Products (Phase I)

9. Kidney Transplant Rejection Preclinical Stage Products

10. Kidney Transplant Rejection Therapeutics Assessment

11. Kidney Transplant Rejection Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Kidney Transplant Rejection Key Companies

14. Kidney Transplant Rejection Key Products

15. Kidney Transplant Rejection Unmet Needs

16 . Kidney Transplant Rejection Market Drivers and Barriers

17. Kidney Transplant Rejection Future Perspectives and Conclusion

18. Kidney Transplant Rejection Analyst Views

19. Appendix

20. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Kidney Transplant Rejection Pipeline Forecast 2024: FDA Approvals, Therapies, and Leading Companies by DelveInsight | Veloxis Pharma, Eledon Pharma, Sangamo, Horizon Therapeutics, CSL Behring, Medeor

AL Amyloidosis Pipeline Assessment 2024: Therapies, Clinical Trials, by DelveInsight | Sorrento Therapeutics, Prothena Therapeutics, Spectrum Pharma, Takeda, Millennium Pharma, Caelum Biosciences

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, AL Amyloidosis pipeline constitutes 10+ key companies continuously working towards developing 10+ AL Amyloidosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“AL Amyloidosis Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the AL Amyloidosis Market.  

 

The AL Amyloidosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the AL Amyloidosis Pipeline Report: 

  • Companies across the globe are diligently working toward developing novel AL Amyloidosis treatment therapies with a considerable amount of success over the years. 

  • AL Amyloidosis companies working in the treatment market are HaemaLogiX, Zentalis Pharmaceuticals, Sorrento Therapeutics, Sanofi, Astellas Pharma GmbH, GlaxoSmithKline, Takeda Oncology, Caelum Biosciences, and others, are developing therapies for the AL Amyloidosis treatment 

  • Emerging AL Amyloidosis therapies in the different phases of clinical trials are- LambdaMab, ZN d5, STI-6129, Isatuximab, Bendamustine, Belantamab mafodotin, Ixazomib, CAEL-101, and others are expected to have a significant impact on the AL Amyloidosis market in the coming years.   

  • In May 2024, Immix Biopharma, Inc. (“ImmixBio), a clinical-stage biopharmaceutical company pioneering cell therapies for autoimmune diseases, has announced new clinical data from its Phase 1b/2a NEXICART-1 (NCT04720313) study. This study investigates the novel, autologous, sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy, NXC-201, in patients with relapsed/refractory AL Amyloidosis (R/R ALA). The data was presented in a late-breaking oral presentation at the 27th Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT) in Baltimore, MD. All participating patients had relapsed/refractory conditions to the standard-of-care Dara-CyBorD (daratumumab combined with cyclophosphamide, bortezomib, and dexamethasone).

  • In September 2023, The FDA has granted orphan drug designation to the next-generation BCMA-directed CAR T-cell therapy NXC-201 (formerly HBI0101) for treating patients with amyloid light chain (AL) amyloidosis.

 

AL Amyloidosis Overview

The most prevalent kind of systemic amyloidosis, AL Amyloidosis, is connected to a plasma cell dyscrasia. A condition affecting the bone marrow results in amyloidosis. The bone marrow in the middle of bones creates “plasma cells,” which are blood system cells.

 

Get a Free Sample PDF Report to know more about AL Amyloidosis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/al-amyloidosis-pipeline-insight

 

Emerging AL Amyloidosis Drugs Under Different Phases of Clinical Development Include:

  • LambdaMab: HaemaLogiX

  • ZN d5: Zentalis Pharmaceuticals

  • STI-6129: Sorrento Therapeutics

  • Isatuximab: Sanofi

  • Bendamustine: Astellas Pharma GmbH

  • Belantamab mafodotin: GlaxoSmithKline

  • Ixazomib: Takeda Oncology

  • CAEL-101: Caelum Biosciences

 

AL Amyloidosis Route of Administration

AL Amyloidosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Intra-articular

  • Intraocular

  • Intrathecal

  • Intravenous

  • Ophthalmic

  • Oral

  • Parenteral

  • Subcutaneous

  • Topical

  • Transdermal

 

AL Amyloidosis Molecule Type

AL Amyloidosis Products have been categorized under various Molecule types, such as

  • Oligonucleotide

  • Peptide

  • Small molecule

 

AL Amyloidosis Pipeline Therapeutics Assessment

  • AL Amyloidosis Assessment by Product Type

  • AL Amyloidosis By Stage and Product Type

  • AL Amyloidosis Assessment by Route of Administration

  • AL Amyloidosis By Stage and Route of Administration

  • AL Amyloidosis Assessment by Molecule Type

  • AL Amyloidosis by Stage and Molecule Type

 

DelveInsight’s AL Amyloidosis Report covers around 10+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

 

Further AL Amyloidosis product details are provided in the report. Download the AL Amyloidosis pipeline report to learn more about the emerging AL Amyloidosis therapies

 

Some of the key companies in the AL Amyloidosis Therapeutics Market include:

Key companies developing therapies for AL Amyloidosis are – Sorrento Therapeutics, Prothena Therapeutics, Spectrum Pharmaceuticals, Takeda, Millennium Pharmaceuticals, Caelum Biosciences, Astellas Pharma GmbH, Oncopeptides, and others.

 

AL Amyloidosis Pipeline Analysis:

The AL Amyloidosis pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of AL Amyloidosis with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for AL Amyloidosis Treatment.

  • AL Amyloidosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • AL Amyloidosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the AL Amyloidosis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about AL Amyloidosis drugs and therapies

 

AL Amyloidosis Pipeline Market Drivers

  • Increase in the number of patients suffering from AL Amyloidosis, increase in awareness about the disease are some of the important factors that are fueling the AL Amyloidosis Market.

 

AL Amyloidosis Pipeline Market Barriers

  • However, high cost of the associated treatment, side effects associated with the treatment and other factors are creating obstacles in the AL Amyloidosis Market growth.

 

Scope of AL Amyloidosis Pipeline Drug Insight    

  • Coverage: Global

  • Key AL Amyloidosis Companies: HaemaLogiX, Zentalis Pharmaceuticals, Sorrento Therapeutics, Sanofi, Astellas Pharma GmbH, GlaxoSmithKline, Takeda Oncology, Caelum Biosciences, and others

  • Key AL Amyloidosis Therapies: LambdaMab, ZN d5, STI-6129, Isatuximab, Bendamustine, Belantamab mafodotin, Ixazomib, CAEL-101, and others

  • AL Amyloidosis Therapeutic Assessment: AL Amyloidosis current marketed and AL Amyloidosis emerging therapies

  • AL Amyloidosis Market Dynamics: AL Amyloidosis market drivers and AL Amyloidosis market barriers 

 

Request for Sample PDF Report for AL Amyloidosis Pipeline Assessment and clinical trials

 

Table of Contents 

1. AL Amyloidosis Report Introduction

2. AL Amyloidosis Executive Summary

3. AL Amyloidosis Overview

4. AL Amyloidosis- Analytical Perspective In-depth Commercial Assessment

5. AL Amyloidosis Pipeline Therapeutics

6. AL Amyloidosis Late Stage Products (Phase II/III)

7. AL Amyloidosis Mid Stage Products (Phase II)

8. AL Amyloidosis Early Stage Products (Phase I)

9. AL Amyloidosis Preclinical Stage Products

10. AL Amyloidosis Therapeutics Assessment

11. AL Amyloidosis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. AL Amyloidosis Key Companies

14. AL Amyloidosis Key Products

15. AL Amyloidosis Unmet Needs

16 . AL Amyloidosis Market Drivers and Barriers

17. AL Amyloidosis Future Perspectives and Conclusion

18. AL Amyloidosis Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: AL Amyloidosis Pipeline Assessment 2024: Therapies, Clinical Trials, by DelveInsight | Sorrento Therapeutics, Prothena Therapeutics, Spectrum Pharma, Takeda, Millennium Pharma, Caelum Biosciences